SCPS - Scopus Bio files application for immuno-oncology RNA therapy in U.S.

Scopus BioPharma ([[SCPS]] +4.5%) has submitted an investigational new drug application ((IND)) to the FDA for its immuno-oncology RNA therapy for the treatment of multiple cancers.The IND filing is a key milestone for the planned Phase 1 clinical trial for B-cell non-Hodgkin lymphoma to be initiated at City of Hope.Scopus' lead drug candidate encompasses both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.

For further details see:

Scopus Bio files application for immuno-oncology RNA therapy in U.S.